Healthcare Jul 06, 2021 09:06 AM (GMT+8) · EqualOcean
Recently, Shenzhen ward life Technology Co., Ltd. (hereinafter referred to as "ward life") announced that it will obtain 100 million yuan of round a financing, which will be jointly invested by Sequoia Capital China fund and Qiming venture capital. It is reported that this round of financing will be used for the company to deepen the pipeline layout of coagulation diagnosis related products, build a strong marketing team and strengthen the supply chain capacity. Ward life was founded in 2016 and has launched a number of patented products. Among them, the series of automatic thromboelastography has become a rare first generation product of the new company, which surpasses the model of imported products, and has entered a number of well-known top three companies. In the past three years, ward life has doubled its revenue in a row. It is reported that in the future, ward life will continue to strengthen its technology accumulation in automation, photoelectric detection, microfluidics and biochemical reagents, and create a large closed-loop coagulation detection system based on thromboelastography, chemiluminescence, platelet analyzer and hemagglutination analyzer.